Induction immunosuppressive therapies in renal transplantation

Gabardi, Steven; Martin, Spencer T.; Roberts, Keri L.; Grafals, Monica
February 2011
American Journal of Health-System Pharmacy;2/1/2011, Vol. 68 Issue 3, p211
Academic Journal
Purpose. Induction immunosuppressive therapies for patients undergoing renal transplantation are reviewed. Summary. The goal of induction therapy is to prevent acute rejection during the early posttransplantation period by providing a high degree of immunosuppression at the time of transplantation. Induction therapy is often considered essential to optimize outcomes, particularly in patients at high risk for poor short-term outcomes. All of the induction immunosuppressive agents currently used are biological agents and are either monoclonal (muromonab-CD3, daclizumab, basiliximab, alemtuzumab) or polyclonal (antithymocyte globulin [equine] or antithymocyte globulin [rabbit]) antibodies. Although antithymocyte globulin (rabbit) is not labeled for induction therapy, it is used for this purpose more than any other agent. Basiliximab is not considered as potent an immunosuppressive agent but has a much more favorable adverse-effect profile compared with antithymocyte globulin (rabbit) and is most commonly used in patients at low risk for acute rejection. Rituximab is being studied for use as induction therapy but to date has not demonstrated any significant benefits over placebo. While head-tohead data are available comparing most induction agents, the final decision on the most appropriate induction therapy for a transplant recipient is highly dependent on preexisting medical conditions, donor characteristics, and the maintenance immunosuppressive regimen to be used. Conclusion. No standard induction immunosuppressive regimen exists for patients undergoing renal transplantation. Antithymocyte globulin (rabbit) is the most commonly used agent, whereas basiliximab appears safer. The choice of regimen depends on the preferences of clinicians and institutions.


Related Articles

  • Ä°ntraepidermal Otoimmün Büllöz Hastalıkların Tedavisi. Kaya, Tamer İrfan // Archives of the Turkish Dermatology & Venerology / Turkderm;2011 Supplement 1, Vol. 45, p44 

    Pemfigus is an autoimmune bullous skin disease, characterized by intraepidermal blisters. It is a severe and potentially life-threatening chronic disease with blisters and erosions on the mucosae and the skin. Treatment options do not differ for two most common types of pemphigus, pemphigus...

  • Pemfigusun Güncel Tedavisi ve Yönetimi. Uzun, Soner // Turkish Journal of Dermatology;sep2012, Vol. 6 Issue 3, p91 

    Corticosteroids decreased the mortality rates of pemphigus as dramatically, and they are still the baseline treatment and cornerstone of pemphigus management. Systemic corticosteroids, in combination with adjuvant corticosteroid-sparing immunosuppressive drugs, are the conventional therapy for...

  • Severe hypogammaglobulinaemia and opportunistic infections after rituximab therapy in a renal transplant recipient. Kahveci, Arzu; Asicioglu, Ebru; Ari, Elif; Arikan, Hakki; Tuglular, Serhan; Ozener, Cetin // Nephrology Dialysis Transplantation;Apr2010, Vol. 3 Issue 2, p165 

    Infectious complications are the leading causes of morbidity and mortality among renal transplant recipients. Hypogammaglobulinaemia may develop as a result of immunosuppressive therapy and is associated with an increased risk of opportunistic infections particularly in the 6-month...

  • Gammaglobulin treatment and anti-IgA antibodies in IgA-deficient patients. Koistinen, Jukka; Heikkila, Marjatta; Leikola, Juhani // British Medical Journal;9/30/1978, Vol. 2 Issue 6142, p923 

    Examines the use of gammaglobulin and anti-immunoglobulin A (IgA) antibodies for the treatment of IgA-deficient patient. Efficacy of the treatment; Stability of antibody titer after treatment; Remission of infection.

  • Advances in diagnosing and managing antibody-mediated rejection. Jordan, Stanley; Reinsmoen, Nancy; Peng, Alice; Lai, Chih-Hung; Cao, Kai; Villicana, Rafael; Toyoda, Mieko; Kahwaji, Joseph; Vo, Ashley // Pediatric Nephrology;Oct2010, Vol. 25 Issue 10, p2035 

    ntibody-mediated rejection (AMR) is a unique, significant, and often severe form of allograft rejection that is not amenable to treatment with standard immunosuppressive medications. Significant advances have occurred in our ability to predict patients at risk for, and to diagnose, AMR. These...

  • Current trends in immunosuppressive therapies for renal transplant recipients. Lee, Ruth-Ann; Gabardi, Steven // American Journal of Health-System Pharmacy;11/15/2012, Vol. 69 Issue 22, p1961 

    Purpose. Current trends in immunosuppressivetherapies for renal transplant recipients are reviewed.Summary. The common premise for immunosuppressive therapies in renal transplantation is to use multiple agents to work on different immunologic targets.The use of a multidrug regimen allows for...

  • Subepidermal Otoimmun Büllöz Hastalıkların Tedavisi. Şavk, Ekin // Archives of the Turkish Dermatology & Venerology / Turkderm;2011 Supplement 1, Vol. 45, p54 

    The common therapeutic goal for all subepidermal bullous diseases is to prevent inflammation and production of pathogenic autoantibodies and/or to facilitate the elimination of these antibodies. Diseases included in this group are the pemphigoids, linear IgA dermatosis, epidermolysis bullosa...

  • Front-line immunosuppressive treatment of acquired aplastic anemia. Dufour, C; Svahn, J; Bacigalupo, A // Bone Marrow Transplantation;Feb2013, Vol. 48 Issue 2, p174 

    In this article, front-line immunosuppressive therapy (IST) for acquired plastic anemia (AA) is illustrated and discussed. Also second-line and salvage options are briefly illustrated. First-line IST should consist of horse anti-thymocyte globulin (ATG) and CsA that has been shown to result in...

  • Should we consider MMF therapy after rituximab for nephrotic syndrome? Filler, Guido; Huang, Shih-Han; Sharma, Ajay // Pediatric Nephrology;Oct2011, Vol. 26 Issue 10, p1759 

    The management of steroid-dependent nephrotic syndrome, especially in patients who have failed to respond to cytotoxic drugs, such as cyclophosphamide, remains challenging. Rituximab represents a new (off-label) therapeutic option. In a significant portion of patients, it has a short serum...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics